2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Journal of the American College of Cardiology

Volumn 70, Issue 2, 2017, Pages 252-289

  Nishimura, Rick A ^a   Otto, Catherine M ^a   Bonow, Robert O ^a   Carabello, Blase A ^a   Erwin, John P ^a   Fleisher, Lee A ^a   Jneid, Hani ^a   Mack, Michael J ^a   McLeod, Christopher J ^a   O'Gara, Patrick T ^a   Rigolin, Vera H ^a   Sundt, Thoralf M ^a   Thompson, Annemarie ^a  

^a NONE

Author keywords

ACC AHA Clinical Practice Guidelines Focused Update; anticoagulation therapy; aortic stenosis; cardiac surgery; heart valves; mitral regurgitation; prosthetic valves; transcatheter aortic valve replacement; tricuspid stenosis; valvular heart disease

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN;

ACUTE MECHANICAL PROSTHETIC VALVE THROMBOSIS; ANTICOAGULANT THERAPY; ANTITHROMBOTIC THERAPY; AORTIC STENOSIS; AORTIC VALVE REPLACEMENT; ARTICLE; ATRIAL FIBRILLATION; BACTERIAL ENDOCARDITIS; CORONARY ARTERY BYPASS GRAFT; DISEASE COURSE; DRUG INDICATION; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE POLICY; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INTERNATIONAL NORMALIZED RATIO; MEDICAL CARE; MEDICAL DEVICE COMPLICATION; METHODOLOGY; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHETIC VALVE DYSFUNCTION; PROSTHETIC VALVE REGURGITATION; PROSTHETIC VALVE STENOSIS; PROSTHETIC VALVE THROMBOSIS; THERAPY; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT INDICATION; VALVULAR HEART DISEASE; ADVISORY COMMITTEE; CARDIOLOGY; CLASSIFICATION; MEDICAL SOCIETY; PROCEDURES; STANDARDS; UNITED STATES;

ADVISORY COMMITTEES; AMERICAN HEART ASSOCIATION; ANTICOAGULANTS; CARDIOLOGY; HEART VALVE DISEASES; HUMANS; TRANSCATHETER AORTIC VALVE REPLACEMENT; UNITED STATES;

EID: 85032587017     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.03.011     Document Type: Article

References (286)

1. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (U.S.). Clinical Practice Guidelines We Can Trust. ed. Washington, DC: Press NA, 2011.
2. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (U.S.). Finding What Works in Health Care: Standards for Systematic Reviews. ed. Washington, DC: Press NA, 2011.
3. Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
4. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association, 2010 Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf. Accessed February 2017.
5. Halperin, J.L., Levine, G.N., Al-Khatib, S.M., Birtcher, K., Bozkurt, B., Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 67 (2016), 1572–1574.
6. Jacobs, A.K., Kushner, F.G., Ettinger, S.M., et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), 213–265.
7. Jacobs, A.K., Anderson, J.L., Halperin, J.L., The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), 1373–1384.
8. Arnett, D.K., Goodman, R.A., Halperin, J.L., Anderson, J.L., Parekh, A.K., Zoghbi, W.A., AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. J Am Coll Cardiol 64 (2014), 1851–1856.
9. Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2438–2488.
10. Nishimura, R., Otto, C.M., Bonow, R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), e57–185.
11. Wilson, W., Taubert, K.A., Gewitz, M., et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116 (2007), 1736–1754.
12. Habib, G., Lancellotti, P., Antunes, M.J., et al. 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 36 (2015), 3075–3128.
13. Glenny, A.M., Oliver, R., Roberts, G.J., Hooper, L., Worthington, H.V., Antibiotics for the prophylaxis of bacterial endocarditis in dentistry. Cochrane Database Syst Rev, 2013, CD003813.
14. (NICE) UNIfHaCE. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. Available at: https://www.nice.org.uk/guidance/cg64. Accessed January 20, 2017.
15. Mougeot, F.K.B., Saunders, S.E., Brennan, M.T., Lockhart, P.B., Associations between bacteremia from oral sources and distant-site infections: tooth brushing versus single tooth extraction. Oral Surg Oral Med Oral Pathol Oral Radiol 119 (2015), 430–435.
16. Desimone, D.C., Tleyjeh, I.M., Correa de Sa, D.D., et al. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. Circulation 126 (2012), 60–64.
17. Dayer, M.J., Jones, S., Prendergast, B., Baddour, L.M., Lockhart, P.B., Thornhill, M.H., Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet 385 (2015), 1219–1228.
18. Duval, X., Delahaye, F., Alla, F., et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol 59 (2012), 1968–1976.
19. Pasquali, S.K., He, X., Mohamad, Z., et al. Trends in endocarditis hospitalizations at US children's hospitals: impact of the 2007 American Heart Association Antibiotic Prophylaxis Guidelines. Am Heart J 163 (2012), 894–899.
20. Pant, S., Patel, N.J., Deshmukh, A., et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol 65 (2015), 2070–2076.
21. Thornhill, M.H., Dayer, M.J., Forde, J.M., et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ, 342, 2011, d2392.
22. Strom, B.L., Abrutyn, E., Berlin, J.A., et al. Risk factors for infective endocarditis: oral hygiene and nondental exposures. Circulation 102 (2000), 2842–2848.
23. Sherman-Weber, S., Axelrod, P., Suh, B., et al. Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literature. Transpl Infect Dis 6 (2004), 165–170.
24. Lockhart, P.B., Brennan, M.T., Sasser, H.C., Fox, P.C., Paster, B.J., Bahrani-Mougeot, F.K., Bacteremia associated with toothbrushing and dental extraction. Circulation 117 (2008), 3118–3125.
25. Geist, S.M., Fitzpatrick, S., Geist, J.R., American Heart Association 2007 guidelines on prevention of infective endocarditis. J Mich Dent Assoc 89 (2007), 50–56.
26. Duval, X., Alla, F., Hoen, B., et al. Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis. Clin Infect Dis 42 (2006), e102–e107.
27. The 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J 36 (2015), 3036–3037.
28. Horstkotte, D., Rosen, H., Friedrichs, W., Loogen, F., Contribution for choosing the optimal prophylaxis of bacterial endocarditis. Eur Heart J 8:suppl J (1987), 379–381.
29. Strom, B.L., Abrutyn, E., Berlin, J.A., et al. Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med 129 (1998), 761–769.
30. Amat-Santos, I.J., Messika-Zeitoun, D., Eltchaninoff, H., et al. Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry. Circulation 131 (2015), 1566–1574.
31. Mangner, N., Woitek, F., Haussig, S., et al. Incidence, predictors, and outcome of patients developing infective endocarditis following transfemoral transcatheter aortic valve replacement. J Am Coll Cardiol 67 (2016), 2907–2908.
32. Karavas, A.N., Filsoufi, F., Mihaljevic, T., Aranki, S.F., Cohn, L.H., Byrne, J.G., Risk factors and management of endocarditis after mitral valve repair. J Heart Valve Dis 11 (2002), 660–664.
33. Gillinov, A.M., Faber, C.N., Sabik, J.F., et al. Endocarditis after mitral valve repair. Ann Thorac Surg 73 (2002), 1813–1816.
34. Pérez-Gómez, F., Alegría, E., Berjón, J., et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 44 (2004), 1557–1566.
35. Noseworthy, P.A., Yao, X., Shah, N.D., Gersh, B.J., Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol 209 (2016), 181–183.
36. Avezum, A., Lopes, R.D., Schulte, P.J., et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 132 (2015), 624–632.
37. Breithardt, G., Baumgartner, H., Berkowitz, S.D., et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 35 (2014), 3377–3385.
38. Ezekowitz, M.D., Nagarakanti, R., Noack, H., et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation 134 (2016), 589–598.
39. Aguilar, M.I., Hart, R., Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev, 2005, CD001927.
40. Olesen, J.B., Lip, G.Y.H., Hansen, M.L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ, 342, 2011, d124.
41. Lytvyn, L., Guyatt, G.H., Manja, V., et al. Patient values and preferences on transcatheter or surgical aortic valve replacement therapy for aortic stenosis: a systematic review. BMJ Open, 6, 2016, e014327.
42. Horstkotte, D., Loogen, F., The natural history of aortic valve stenosis. Eur Heart J 9:Suppl E (1988), 57–64.
43. O'Brien, S.M., Shahian, D.M., Filardo, G., et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2—isolated valve surgery. Ann Thorac Surg 88 (2009), S23–S42.
44. Freeman, R.V., Otto, C.M., Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111 (2005), 3316–3326.
45. Kvidal, P., Bergström, R., Hörte, L.G., Stahle, E., Observed and relative survival after aortic valve replacement. J Am Coll Cardiol 35 (2000), 747–756.
46. Murphy, E.S., Lawson, R.M., Starr, A., Rahimtoola, S.H., Severe aortic stenosis in patients 60 years of age or older: left ventricular function and 10-year survival after valve replacement. Circulation 64 (1981), II184–II188.
47. Rosenhek, R., Aortic stenosis: disease severity, progression, timing of intervention and role in monitoring transcatheter valve implanation. Otto, C.M., (eds.) The Practice of Clinical Echocardiography, 4 ed, 2012, Elsevier/Saunders, Philadelphia, PA, 425–449.
48. Schwarz, F., Baumann, P., Manthey, J., et al. The effect of aortic valve replacement on survival. Circulation 66 (1982), 1105–1110.
49. Adams, D.H., Popma, J.J., Reardon, M.J., et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370 (2014), 1790–1798.
50. Mack, M.J., Leon, M.B., Smith, C.R., et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385 (2015), 2477–2484.
51. Deeb, G.M., Reardon, M.J., Chetcuti, S., et al. Three-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol 67 (2016), 2565–2574.
52. Holmes, D.R. Jr., Nishimura, R.A., Grover, F.L., et al. Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. J Am Coll Cardiol 66 (2015), 2813–2823.
53. Makkar, R.R., Fontana, G.P., Jilaihawi, H., et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 366 (2012), 1696–1704.
54. Smith, C.R., Leon, M.B., Mack, M.J., et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364 (2011), 2187–2198.
55. Eltchaninoff, H., Prat, A., Gilard, M., et al. Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur Heart J 32 (2011), 191–197.
56. Rodés-Cabau, J., Webb, J.G., Cheung, A., et al. Long-term outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience. J Am Coll Cardiol 60 (2012), 1864–1875.
57. Abdel-Wahab, M., Neumann, F.J., Mehilli, J., et al. One-year outcomes after transcatheter aortic valve replacement with balloon-expandable versus self-expandable valves: results from the CHOICE randomized clinical trial. J Am Coll Cardiol 66 (2015), 791–800.
58. Kapadia, S.R., Leon, M.B., Makkar, R.R., et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385 (2015), 2485–2491.
59. Popma, J.J., Adams, D.H., Reardon, M.J., et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 63 (2014), 1972–1981.
60. Leon, M.B., Smith, C.R., Mack, M., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363 (2010), 1597–1607.
61. Kodali, S.K., Williams, M.R., Smith, C.R., et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 366 (2012), 1686–1695.
62. Leon, M.B., Smith, C.R., Mack, M.J., et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374 (2016), 1609–1620.
63. Thourani, V.H., Kodali, S., Makkar, R.R., et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 387 (2016), 2218–2225.
64. Siemieniuk, R.A., Agoritsas, T., Manja, V., et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis. BMJ, 354, 2016, i5130.
65. Foroutan, F., Guyatt, G.H., O'Brien, K., et al. Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies. BMJ, 354, 2016, i5065.
66. Vandvik, P.O., Otto, C.M., Siemieniuk, R.A., et al. Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: a clinical practice guideline. BMJ, 354, 2016, i5085.
67. Uretsky, S., Gillam, L., Lang, R., et al. Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial. J Am Coll Cardiol 65 (2015), 1078–1088.
68. Grayburn, P.A., Carabello, B., Hung, J., et al. Defining “severe” secondary mitral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol 64 (2014), 2792–2801.
69. Acker, M.A., Parides, M.K., Perrault, L.P., et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 370 (2014), 23–32.
70. Goldstein, D., Moskowitz, A.J., Gelijns, A.C., et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med 374 (2016), 344–353.
71. Michler, R.E., Smith, P.K., Parides, M.K., et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 374 (2016), 1932–1941.
72. Smith, P.K., Puskas, J.D., Ascheim, D.D., et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 371 (2014), 2178–2188.
73. David, T.E., Armstrong, S., McCrindle, B.W., Manlhiot, C., Late outcomes of mitral valve repair for mitral regurgitation due to degenerative disease. Circulation 127 (2013), 1485–1492.
74. Gillinov, A.M., Mihaljevic, T., Blackstone, E.H., et al. Should patients with severe degenerative mitral regurgitation delay surgery until symptoms develop?. Ann Thorac Surg 90 (2010), 481–488.
75. Tribouilloy, C.M., Enriquez-Sarano, M., Schaff, H.V., et al. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications. Circulation 99 (1999), 400–405.
76. Crawford, M.H., Souchek, J., Oprian, C.A., et al. Determinants of survival and left ventricular performance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular Heart Disease. Circulation 81 (1990), 1173–1181.
77. Enriquez-Sarano, M., Tajik, A.J., Schaff, H.V., et al. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol 24 (1994), 1536–1543.
78. Grigioni, F., Enriquez-Sarano, M., Ling, L.H., et al. Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol 34 (1999), 2078–2085.
79. Grigioni, F., Tribouilloy, C., Avierinos, J.F., et al. Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. J Am Coll Cardiol Img 1 (2008), 133–141.
80. Schuler, G., Peterson, K.L., Johnson, A., et al. Temporal response of left ventricular performance to mitral valve surgery. Circulation 59 (1979), 1218–1231.
81. Starling, M.R., Effects of valve surgery on left ventricular contractile function in patients with long-term mitral regurgitation. Circulation 92 (1995), 811–818.
82. Tribouilloy, C., Grigioni, F., Avierinos, J.F., et al. Survival implication of left ventricular end-systolic diameter in mitral regurgitation due to flail leaflets a long-term follow-up multicenter study. J Am Coll Cardiol 54 (2009), 1961–1968.
83. STS online risk calculator. Available at: http://riskcalcstsorg/stswebriskcalc Accessed January 20, 2017.
84. Braunberger, E., Deloche, A., Berrebi, A., et al. Very long-term results (more than 20 years) of valve repair with Carpentier's techniques in nonrheumatic mitral valve insufficiency. Circulation 104 (2001), I8–I11.
85. Cohn, L.H., Surgery for mitral regurgitation. JAMA 260 (1988), 2883–2887.
86. Cosgrove, D.M., Chavez, A.M., Lytle, B.W., et al. Results of mitral valve reconstruction. Circulation 74 (1986), I82–I87.
87. David, T.E., Uden, D.E., Strauss, H.D., The importance of the mitral apparatus in left ventricular function after correction of mitral regurgitation. Circulation 68 (1983), II76–II82.
88. David, T.E., Burns, R.J., Bacchus, C.M., Druck, M.N., Mitral valve replacement for mitral regurgitation with and without preservation of chordae tendineae. J Thorac Cardiovasc Surg 88 (1984), 718–725.
89. David, T.E., Ivanov, J., Armstrong, S., Christie, D., Rakowski, H., A comparison of outcomes of mitral valve repair for degenerative disease with posterior, anterior, and bileaflet prolapse. J Thorac Cardiovasc Surg 130 (2005), 1242–1249.
90. Gammie, J.S., Sheng, S., Griffith, B.P., et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg 87 (2009), 1431–1437 discussion 7–349.
91. Goldman, K.E., Dental management of patients with bone marrow and solid organ transplantation. Dent Clin North Am 50 (2006), 659–676 viii.
92. Hansen, D.E., Sarris, G.E., Niczyporuk, M.A., Derby, G.C., Cahill, P.D., Miller, D.C., Physiologic role of the mitral apparatus in left ventricular regional mechanics, contraction synergy, and global systolic performance. J Thorac Cardiovasc Surg 97 (1989), 521–533.
93. Hennein, H.A., Swain, J.A., McIntosh, C.L., Bonow, R.O., Stone, C.D., Clark, R.E., Comparative assessment of chordal preservation versus chordal resection during mitral valve replacement. J Thorac Cardiovasc Surg 99 (1990), 828–836 discussion 36–37.
94. Horskotte, D., Schulte, H.D., Bircks, W., Strauer, B.E., The effect of chordal preservation on late outcome after mitral valve replacement: a randomized study. J Heart Valve Dis 2 (1993), 150–158.
95. McClure, R.S., Athanasopoulos, L.V., McGurk, S., Davidson, M.J., Couper, G.S., Cohn, L.H., One thousand minimally invasive mitral valve operations: early outcomes, late outcomes, and echocardiographic follow-up. J Thorac Cardiovasc Surg 145 (2013), 1199–1206.
96. Rozich, J.D., Carabello, B.A., Usher, B.W., Kratz, J.M., Bell, A.E., Zile, M.R., Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance. Circulation 86 (1992), 1718–1726.
97. Rushmer, R.F., Initial phase of ventricular systole: asynchronous contraction. Am J Physiol 184 (1956), 188–194.
98. Sarris, G.E., Cahill, P.D., Hansen, D.E., Derby, G.C., Miller, D.C., Restoration of left ventricular systolic performance after reattachment of the mitral chordae tendineae. The importance of valvular-ventricular interaction. J Thorac Cardiovasc Surg 95 (1988), 969–979.
99. Vassileva, C.M., Mishkel, G., McNeely, C., et al. Long-term survival of patients undergoing mitral valve repair and replacement: a longitudinal analysis of Medicare fee-for-service beneficiaries. Circulation 127 (2013), 1870–1876.
100. Badhwar, V., Peterson, E.D., Jacobs, J.P., et al. Longitudinal outcome of isolated mitral repair in older patients: results from 14,604 procedures performed from 1991 to 2007. Ann Thorac Surg 94 (2012), 1870–1879.
101. Bolling, S.F., Li, S., O'Brien, S.M., Brennan, J.M., Prager, R.L., Gammie, J.S., Predictors of mitral valve repair: clinical and surgeon factors. Ann Thorac Surg 90 (2010), 1904–1911 discussion 12.
102. Chauvaud, S., Fuzellier, J.F., Berrebi, A., Deloche, A., Fabiani, J.N., Carpentier, A., Long-term (29 years) results of reconstructive surgery in rheumatic mitral valve insufficiency. Circulation 104 (2001), I12–I15.
103. Chikwe, J., Goldstone, A.B., Passage, J., et al. A propensity score-adjusted retrospective comparison of early and mid-term results of mitral valve repair versus replacement in octogenarians. Eur Heart J 32 (2011), 618–626.
104. Grossi, E.A., Galloway, A.C., Miller, J.S., et al. Valve repair versus replacement for mitral insufficiency: when is a mechanical valve still indicated?. J Thorac Cardiovasc Surg 115 (1998), 389–396.
105. Gillinov, A.M., Blackstone, E.H., Cosgrove, D.M. III, et al. Mitral valve repair with aortic valve replacement is superior to double valve replacement. J Thorac Cardiovasc Surg 125 (2003), 1372–1387.
106. Suri, R.M., Vanoverschelde, J.L., Grigioni, F., et al. Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. JAMA 310 (2013), 609–616.
107. Rosenhek, R., Rader, F., Klaar, U., et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 113 (2006), 2238–2244.
108. Gillinov, A.M., Blackstone, E.H., Nowicki, E.R., et al. Valve repair versus valve replacement for degenerative mitral valve disease. J Thorac Cardiovasc Surg 135 (2008), 885–893 93.e1–2.
109. Duran, C.M., Gometza, B., Saad, E., Valve repair in rheumatic mitral disease: an unsolved problem. J Card Surg 9 (1994), 282–285.
110. Suri, R.M., Schaff, H.V., Dearani, J.A., et al. Recovery of left ventricular function after surgical correction of mitral regurgitation caused by leaflet prolapse. J Thorac Cardiovasc Surg 137 (2009), 1071–1076.
111. Kang, D.H., Kim, J.H., Rim, J.H., et al. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation 119 (2009), 797–804.
112. Tribouilloy, C., Rusinaru, D., Szymanski, C., et al. Predicting left ventricular dysfunction after valve repair for mitral regurgitation due to leaflet prolapse: additive value of left ventricular end-systolic dimension to ejection fraction. Eur J Echocardiogr 12 (2011), 702–710.
113. Enriquez-Sarano, M., Suri, R.M., Clavel, M.A., et al. Is there an outcome penalty linked to guideline-based indications for valvular surgery? Early and long-term analysis of patients with organic mitral regurgitation. J Thorac Cardiovasc Surg 150 (2015), 50–58.
114. Quintana, E., Suri, R.M., Thalji, N.M., et al. Left ventricular dysfunction after mitral valve repair—the fallacy of “normal” preoperative myocardial function. J Thorac Cardiovasc Surg 148 (2014), 2752–2760.
115. Suri, R.M., Schaff, H.V., Dearani, J.A., et al. Determinants of early decline in ejection fraction after surgical correction of mitral regurgitation. J Thorac Cardiovasc Surg 136 (2008), 442–447.
116. Naji, P., Griffin, B.P., Barr, T., et al. Importance of exercise capacity in predicting outcomes and determining optimal timing of surgery in significant primary mitral regurgitation. J Am Heart Assoc, 3, 2014, e001010.
117. Cox, J.L., The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg 101 (1991), 584–592.
118. Ghoreishi, M., Evans, C.F., DeFilippi, C.R., et al. Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: implications for timing of surgery. J Thorac Cardiovasc Surg 142 (2011), 1439–1452.
119. Kawaguchi, A.T., Kosakai, Y., Sasako, Y., Eishi, K., Nakano, K., Kawashima, Y., Risks and benefits of combined maze procedure for atrial fibrillation associated with organic heart disease. J Am Coll Cardiol 28 (1996), 985–990.
120. Kobayashi, J., Kosakai, Y., Isobe, F., et al. Rationale of the Cox Maze procedure for atrial fibrillation during redo mitral valve operations. J Thorac Cardiovasc Surg 112 (1996), 1216–1221 discussion 22.
121. Ngaage, D.L., Schaff, H.V., Mullany, C.J., et al. Influence of preoperative atrial fibrillation on late results of mitral repair: is concomitant ablation justified?. Ann Thorac Surg 84 (2007), 434–442 discussion 42–43.
122. Olasinska-Wisniewska, A., Mularek-Kubzdela, T., Grajek, S., et al. Impact of atrial remodeling on heart rhythm after radiofrequency ablation and mitral valve operations. Ann Thorac Surg 93 (2012), 1449–1455.
123. Raine, D., Dark, J., Bourke, J.P., Effect of mitral valve repair/replacement surgery on atrial arrhythmia behavior. J Heart Valve Dis 13 (2004), 615–621.
124. Feldman, T., Foster, E., Glower, D.D., et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 364 (2011), 1395–1406.
125. Fattouch, K., Guccione, F., Sampognaro, R., et al. POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial. J Thorac Cardiovasc Surg 138 (2009), 278–285.
126. Whitlow, P.L., Feldman, T., Pedersen, W.R., et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol 59 (2012), 130–139.
127. Wu, A.H., Aaronson, K.D., Bolling, S.F., Pagani, F.D., Welch, K., Koelling, T.M., Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 45 (2005), 381–387.
128. Asgar, A.W., Mack, M.J., Stone, G.W., Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol 65 (2015), 1231–1248.
129. Obadia, J.F., Armoiry, X., Iung, B., et al. The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation. EuroIntervention 10 (2015), 1354–1360.
130. Grigioni, F., Enriquez-Sarano, M., Zehr, K.J., Bailey, K.R., Tajik, A.J., Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 103 (2001), 1759–1764.
131. Lancellotti, P., Gérard, P.L., Piérard, L.A., Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J 26 (2005), 1528–1532.
132. Trichon, B.H., Felker, G.M., Shaw, L.K., Cabell, C.H., O'Connor, C.M., Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol 91 (2003), 538–543.
133. Rossi, A., Dini, F.L., Faggiano, P., et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 97 (2011), 1675–1680.
134. Mihaljevic, T., Lam, B.K., Rajeswaran, J., et al. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol 49 (2007), 2191–2201.
135. Harris, K.M., Sundt, T.M. III, Aeppli, D., Sharma, R., Barzilai, B., Can late survival of patients with moderate ischemic mitral regurgitation be impacted by intervention on the valve?. Ann Thorac Surg 74 (2002), 1468–1475.
136. Benedetto, U., Melina, G., Roscitano, A., et al. Does combined mitral valve surgery improve survival when compared to revascularization alone in patients with ischemic mitral regurgitation? A meta-analysis on 2479 patients. J Cardiovasc Med (Hagerstown) 10 (2009), 109–114.
137. Deja, M.A., Grayburn, P.A., Sun, B., et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation 125 (2012), 2639–2648.
138. Cohn, L.H., Rizzo, R.J., Adams, D.H., et al. The effect of pathophysiology on the surgical treatment of ischemic mitral regurgitation: operative and late risks of repair versus replacement. Eur J Cardiothorac Surg 9 (1995), 568–574.
139. Chan, K.M.J., Punjabi, P.P., Flather, M., et al. Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation 126 (2012), 2502–2510.
140. Lim, D.S., Reynolds, M.R., Feldman, T., et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol 64 (2013), 182–192.
141. van Geldorp, M.W.A., Eric Jamieson, W.R., Kappetein, A.P., et al. Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant-related event risk against reoperation risk. J Thorac Cardiovasc Surg 137 (2009), 881–886 6e1–5.
142. Glaser, N., Jackson, V., Holzmann, M.J., Franco-Cereceda, A., Sartipy, U., Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50-69 years. Eur Heart J 37 (2016), 2658–2667.
143. Chikwe, J., Chiang, Y.P., Egorova, N.N., Itagaki, S., Adams, D.H., Survival and outcomes following bioprosthetic vs mechanical mitral valve replacement in patients aged 50 to 69 years. JAMA 313 (2015), 1435–1442.
144. McClure, R.S., McGurk, S., Cevasco, M., et al. Late outcomes comparison of nonelderly patients with stented bioprosthetic and mechanical valves in the aortic position: a propensity-matched analysis. J Thorac Cardiovasc Surg 148 (2014), 1931–1939.
145. Chiang, Y.P., Chikwe, J., Moskowitz, A.J., Itagaki, S., Adams, D.H., Egorova, N.N., Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. JAMA 312 (2014), 1323–1329.
146. Repack, A., Ziganshin, B.A., Elefteriades, J.A., Mukherjee, S.K., Comparison of quality of life perceived by patients with bioprosthetic versus mechanical valves after composite aortic root replacement. Cardiology 133 (2016), 3–9.
147. Dunning, J., Gao, H., Chambers, J., et al. Aortic valve surgery: marked increases in volume and significant decreases in mechanical valve use—an analysis of 41,227 patients over 5 years from the Society for Cardiothoracic Surgery in Great Britain and Ireland National database. J Thorac Cardiovasc Surg 142 (2011), 776–782.e3.
148. Rahimtoola, S.H., Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol 55 (2010), 2413–2426.
149. Weber, A., Noureddine, H., Englberger, L., et al. Ten-year comparison of pericardial tissue valves versus mechanical prostheses for aortic valve replacement in patients younger than 60 years of age. J Thorac Cardiovasc Surg 144 (2012), 1075–1083.
150. Bourguignon, T., Bouquiaux-Stablo, A.L., Candolfi, P., et al. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg 99 (2015), 831–837.
151. Bourguignon, T., Bouquiaux-Stablo, A.L., Loardi, C., et al. Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. J Thorac Cardiovasc Surg 148 (2014), 2004–2011.e1.
152. Ye, J., Cheung, A., Yamashita, M., et al. Transcatheter aortic and mitral valve-in-valve implantation for failed surgical bioprosthetic valves: an eight-year single-center experience. J Am Coll Cardiol Intv 8 (2015), 1735–1744.
153. Dvir, D., Webb, J., Brecker, S., et al. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation 126 (2012), 2335–2344.
154. Dvir, D., Webb, J.G., Bleiziffer, S., et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 312 (2014), 162–170.
155. Hammermeister, K., Sethi, G.K., Henderson, W.G., Grover, F.L., Oprian, C., Rahimtoola, S.H., Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 36 (2000), 1152–1158.
156. Chan, V., Jamieson, W.R.E., Germann, E., et al. Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after aortic valve replacement. J Thorac Cardiovasc Surg 131 (2006), 1267–1273.
157. Kaneko, T., Aranki, S., Javed, Q., et al. Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old. J Thorac Cardiovasc Surg 147 (2014), 117–126.
158. Badhwar, V., Ofenloch, J.C., Rovin, J.D., van Gelder, H.M., Jacobs, J.P., Noninferiority of closely monitored mechanical valves to bioprostheses overshadowed by early mortality benefit in younger patients. Ann Thorac Surg 93 (2012), 748–753.
159. Brown, M.L., Schaff, H.V., Lahr, B.D., et al. Aortic valve replacement in patients aged 50 to 70 years: improved outcome with mechanical versus biologic prostheses. J Thorac Cardiovasc Surg 135 (2008), 878–884 discussion 84.
160. Kulik, A., Bédard, P., Lam, B.K., et al. Mechanical versus bioprosthetic valve replacement in middle-aged patients. Eur J Cardiothorac Surg 30 (2006), 485–491.
161. Bourguignon, T., El Khoury, R., Candolfi, P., et al. Very long-term outcomes of the Carpentier-Edwards Perimount aortic valve in patients aged 60 or younger. Ann Thorac Surg 100 (2015), 853–859.
162. McClure, R.S., Narayanasamy, N., Wiegerinck, E., et al. Late outcomes for aortic valve replacement with the Carpentier-Edwards pericardial bioprosthesis: up to 17-year follow-up in 1,000 patients. Ann Thorac Surg 89 (2010), 1410–1416.
163. Banbury, M.K., Cosgrove, D.M. III, Thomas, J.D., et al. Hemodynamic stability during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg 73 (2002), 1460–1465.
164. Borger, M.A., Ivanov, J., Armstrong, S., Christie-Hrybinsky, D., Feindel, C.M., David, T.E., Twenty-year results of the Hancock II bioprosthesis. J Heart Valve Dis 15 (2006), 49–55 discussion -6.
165. Dellgren, G., David, T.E., Raanani, E., Armstrong, S., Ivanov, J., Rakowski, H., Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg 124 (2002), 146–154.
166. Mykén, P.S., Bech-Hansen, O., A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg 137 (2009), 76–81.
167. Charitos, E.I., Takkenberg, J.J.M., Hanke, T., et al. Reoperations on the pulmonary autograft and pulmonary homograft after the Ross procedure: an update on the German Dutch Ross Registry. J Thorac Cardiovasc Surg 144 (2012), 813–821 discussion 21–23.
168. El-Hamamsy, I., Eryigit, Z., Stevens, L.M., et al. Long-term outcomes after autograft versus homograft aortic root replacement in adults with aortic valve disease: a randomised controlled trial. Lancet 376 (2010), 524–531.
169. Mokhles, M.M., Rizopoulos, D., Andrinopoulou, E.R., et al. Autograft and pulmonary allograft performance in the second post-operative decade after the Ross procedure: insights from the Rotterdam Prospective Cohort Study. Eur Heart J 33 (2012), 2213–2224.
170. Edmunds, L.H. Jr., Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 44 (1987), 430–445.
171. Tiede, D.J., Nishimura, R.A., Gastineau, D.A., Mullany, C.J., Orszulak, T.A., Schaff, H.V., Modern management of prosthetic valve anticoagulation. Mayo Clin Proc 73 (1998), 665–680.
172. Aziz, F., Corder, M., Wolffe, J., Comerota, A.J., Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J Vasc Surg 54 (2011), 1404–1407.
173. Chiquette, E., Amato, M.G., Bussey, H.I., Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 158 (1998), 1641–1647.
174. Wittkowsky, A.K., Nutescu, E.A., Blackburn, J., et al. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting. Chest 130 (2006), 1385–1389.
175. Lalonde, L., Martineau, J., Blais, N., et al. Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Am Heart J 156 (2008), 148–154.
176. Witt, D.M., Sadler, M.A., Shanahan, R.L., Mazzoli, G., Tillman, D.J., Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 127 (2005), 1515–1522.
177. Locke, C., Ravnan, S.L., Patel, R., Uchizono, J.A., Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service. Pharmacotherapy 25 (2005), 685–689.
178. Whitlock, R.P., Sun, J.C., Fremes, S.E., Rubens, F.D., Teoh, K.H., Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e576S–e600.
179. Cannegieter, S.C., Rosendaal, F.R., Briët, E., Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89 (1994), 635–641.
180. Cannegieter, S.C., Rosendaal, F.R., Wintzen, A.R., van der Meer, F.J., Vandenbroucke, J.P., Briet, E., Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333 (1995), 11–17.
181. Schlitt, A., von Bardeleben, R.S., Ehrlich, A., et al. Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thromb Res 109 (2003), 131–135.
182. Stein, P.D., Alpert, J.S., Bussey, H.I., Dalen, J.E., Turpie, A.G., Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 119 (2001), 220S–227S.
183. Sun, J.C.J., Davidson, M.J., Lamy, A., Eikelboom, J.W., Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 374 (2009), 565–576.
184. Acar, J., Iung, B., Boissel, J.P., et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 94 (1996), 2107–2112.
185. Hering, D., Piper, C., Bergemann, R., et al. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. Chest 127 (2005), 53–59.
186. Torella, M., Torella, D., Chiodini, P., et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the “LOWERING-IT” Trial. Am Heart J 160 (2010), 171–178.
187. Horstkotte, D., Scharf, R.E., Schultheiss, H.P., Intracardiac thrombosis: patient-related and device-related factors. J Heart Valve Dis 4 (1995), 114–120.
188. Pruefer, D., Dahm, M., Dohmen, G., Horstkotte, D., Bergemann, R., Oelert, H., Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5). Eur Heart J Suppl 3:Suppl Q (2001), Q39–Q43.
189. Meschengieser, S.S., Fondevila, C.G., Frontroth, J., Santarelli, M.T., Lazzari, M.A., Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 113 (1997), 910–916.
190. Turpie, A.G., Gent, M., Laupacis, A., et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 329 (1993), 524–529.
191. Aramendi, J.I., Mestres, C.A., Campos, V., Martinez-Leon, J., Munoz, G., Navas, C., Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 27 (2005), 854–860.
192. Colli, A., Mestres, C.A., Castella, M., Gherli, T., Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis 16 (2007), 667–671.
193. Heras, M., Chesebro, J.H., Fuster, V., et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 25 (1995), 1111–1119.
194. Nuñez, L., Gil Aguado, M., Larrea, J.L., Celemin, D., Oliver, J., Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg 37 (1984), 84–87.
195. Brennan, J.M., Edwards, F.H., Zhao, Y., et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 60 (2012), 971–977.
196. Egbe, A.C., Pislaru, S.V., Pellikka, P.A., et al. Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic predictors. J Am Coll Cardiol 66 (2015), 2285–2294.
197. Mérie, C., Køber, L., Skov Olsen, P., et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 308 (2012), 2118–2125.
198. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
199. Douketis, J.D., Spyropoulos, A.C., Kaatz, S., et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373 (2015), 823–833.
200. Eikelboom, J.W., Connolly, S.J., Brueckmann, M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369 (2013), 1206–1214.
201. Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
202. Granger, C.B., Alexander, J.H., McMurray, J.J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
203. Makkar, R.R., Fontana, G., Jilaihawi, H., et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373 (2015), 2015–2024.
204. Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
205. Sundt, T.M., Zehr, K.J., Dearani, J.A., et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?. J Thorac Cardiovasc Surg 129 (2005), 1024–1031.
206. Russo, A., Grigioni, F., Avierinos, J.F., et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol 51 (2008), 1203–1211.
207. ElBardissi, A.W., DiBardino, D.J., Chen, F.Y., Yamashita, M.H., Cohn, L.H., Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?. J Thorac Cardiovasc Surg 139 (2010), 1137–1145.
208. Levine, G.N., Bates, E.R., Bittl, J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
209. Puskas, J., Gerdisch, M., Nichols, D., et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized On-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg 147 (2014), 1202–1210 discussion 10–11.
210. Hansson, N.C., Grove, E.L., Andersen, H.R., et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol 68 (2016), 2059–2069.
211. Pache, G., Schoechlin, S., Blanke, P., et al. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J 37 (2016), 2263–2271.
212. FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. December 19, 2012. 2012.
213. Van de Werf, F., Brueckmann, M., Connolly, S.J., et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 163 (2012), 931–937.e1.
214. Douketis, J.D., Spyropoulos, A.C., Spencer, F.A., et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Erratum. Chest 141 (2012), e326S–e350.
215. Pengo, V., Palareti, G., Cucchini, U., et al. Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). Clin Appl Thromb Hemost 13 (2007), 241–248.
216. Barbetseas, J., Nagueh, S.F., Pitsavos, C., Toutouzas, P.K., Quinones, M.A., Zoghbi, W.A., Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. J Am Coll Cardiol 32 (1998), 1410–1417.
217. Gündüz, S., Özkan, M., Kalçik, M., et al. Sixty-four-section cardiac computed tomography in mechanical prosthetic heart valve dysfunction: thrombus or pannus. Circ Cardiovasc Imaging, 8, 2015, e003246.
218. Cianciulli, T.E., Lax, J.A., Beck, M.A., et al. Cinefluoroscopic assessment of mechanical disc prostheses: its value as a complementary method to echocardiography. J Heart Valve Dis 14 (2005), 664–673.
219. Montorsi, P., De Bernardi, F., Muratori, M., Cavoretto, D., Pepi, M., Role of cine-fluoroscopy, transthoracic, and transesophageal echocardiography in patients with suspected prosthetic heart valve thrombosis. Am J Cardiol 85 (2000), 58–64.
220. Muratori, M., Montorsi, P., Teruzzi, G., et al. Feasibility and diagnostic accuracy of quantitative assessment of mechanical prostheses leaflet motion by transthoracic and transesophageal echocardiography in suspected prosthetic valve dysfunction. Am J Cardiol 97 (2006), 94–100.
221. Suh, Y.J., Lee, S., Im, D.J., et al. Added value of cardiac computed tomography for evaluation of mechanical aortic valve: emphasis on evaluation of pannus with surgical findings as standard reference. Int J Cardiol 214 (2016), 454–460.
222. Symersky, P., Budde, R.P.J., de Mol, B.A.J.M., Prokop, M., Comparison of multidetector-row computed tomography to echocardiography and fluoroscopy for evaluation of patients with mechanical prosthetic valve obstruction. Am J Cardiol 104 (2009), 1128–1134.
223. Gürsoy, O.M., Karakoyun, S., Kalçik, M., Ozkan, M., The incremental value of RT three-dimensional TEE in the evaluation of prosthetic mitral valve ring thrombosis complicated with thromboembolism. Echocardiography 30 (2013), E198–E201.
224. Tong, A.T., Roudaut, R., Özkan, M., et al. Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol 43 (2004), 77–84.
225. Keuleers, S., Herijgers, P., Herregods, M.C., et al. Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis. Am J Cardiol 107 (2011), 275–279.
226. Roudaut, R., Lafitte, S., Roudaut, M.F., et al. Management of prosthetic heart valve obstruction: fibrinolysis versus surgery. Early results and long-term follow-up in a single-centre study of 263 cases. Arch Cardiovasc Dis 102 (2009), 269–277.
227. Karthikeyan, G., Math, R.S., Mathew, N., et al. Accelerated infusion of streptokinase for the treatment of left-sided prosthetic valve thrombosis: a randomized controlled trial. Circulation 120 (2009), 1108–1114.
228. Cáceres-Lóriga, F.M., Pérez-López, H., Morlans-Hernandez, K., et al. Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients. J Thromb Thrombolysis 21 (2006), 185–190.
229. Özkan, M., Gündüz, S., Biteker, M., et al. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. J Am Coll Cardiol Img 6 (2013), 206–216.
230. Nagy, A., Dénes, M., Lengyel, M., Predictors of the outcome of thrombolytic therapy in prosthetic mitral valve thrombosis: a study of 62 events. J Heart Valve Dis 18 (2009), 268–275.
231. Özkan, M., Çakal, B., Karakoyun, S., et al. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator. Circulation 128 (2013), 532–540.
232. Deviri, E., Sareli, P., Wisenbaugh, T., Cronje, S.L., Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol 17 (1991), 646–650.
233. Karthikeyan, G., Senguttuvan, N.B., Joseph, J., Devasenapathy, N., Bahl, V.K., Airan, B., Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies. Eur Heart J 34 (2013), 1557–1566.
234. Huang, G., Schaff, H.V., Sundt, T.M., Rahimtoola, S.H., Treatment of obstructive thrombosed prosthetic heart valve. J Am Coll Cardiol 62 (2013), 1731–1736.
235. Özkan, M., Gündüz, S., Gürsoy, O.M., et al. Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial. Am Heart J 170 (2015), 409–418.
236. Laschinger, J.C., Wu, C., Ibrahim, N.G., Shuren, J.E., Reduced leaflet motion in bioprosthetic aortic valves—the FDA perspective. N Engl J Med 373 (2015), 1996–1998.
237. Pibarot, P., Dumesnil, J.G., Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation 119 (2009), 1034–1048.
238. Koene, B.M., Soliman Hamad, M.A., Bouma, W., et al. Impact of prosthesis-patient mismatch on early and late mortality after aortic valve replacement. J Cardiothorac Surg, 8, 2013, 96.
239. Maganti, M., Rao, V., Armstrong, S., Feindel, C.M., Scully, H.E., David, T.E., Redo valvular surgery in elderly patients. Ann Thorac Surg 87 (2009), 521–525.
240. Leontyev, S., Borger, M.A., Davierwala, P., et al. Redo aortic valve surgery: early and late outcomes. Ann Thorac Surg 91 (2011), 1120–1126.
241. Kaneko, T., Vassileva, C.M., Englum, B., et al. Contemporary outcomes of repeat aortic valve replacement: a benchmark for transcatheter valve-in-valve procedures. Ann Thorac Surg 100 (2015), 1298–1304 discussion 304.
242. Jander, N., Kienzle, R.P., Kayser, G., Neumann, F.J., Gohlke-Baerwolf, C., Minners, J., Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position. Am J Cardiol 109 (2012), 257–262.
243. Butnaru, A., Shaheen, J., Tzivoni, D., Tauber, R., Bitran, D., Silberman, S., Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol 112 (2013), 1439–1444.
244. Pislaru, S.V., Hussain, I., Pellikka, P.A., et al. Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 47 (2015), 725–732.
245. De Marchena, E., Mesa, J., Pomenti, S., et al. Thrombus formation following transcatheter aortic valve replacement. J Am Coll Cardiol Intv 8 (2015), 728–739.
246. Latib, A., Naganuma, T., Abdel-Wahab, M., et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv, 8, 2015.
247. Webb, J.G., Wood, D.A., Ye, J., et al. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation 121 (2010), 1848–1857.
248. Phan, K., Zhao, D.F., Wang, N., Huo, Y.R., Di, E.M., Yan, T.D., Transcatheter valve-in-valve implantation versus reoperative conventional aortic valve replacement: a systematic review. J Thorac Dis 8 (2016), E83–E93.
249. Administration USFaD. FDA expands use of CoreValue System for aortic “valve-in-valve replacement”. March 30, 2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm440535.htm. Accessed January 20, 2017.
250. Akins, C.W., Bitondo, J.M., Hilgenberg, A.D., Vlahakes, G.J., Madsen, J.C., MacGillivray, T.E., Early and late results of the surgical correction of cardiac prosthetic paravalvular leaks. J Heart Valve Dis 14 (2005), 792–799 discussion 9–800.
251. Miller, D.L., Morris, J.J., Schaff, H.V., Mullany, C.J., Nishimura, R.A., Orszulak, T.A., Reoperation for aortic valve periprosthetic leakage: identification of patients at risk and results of operation. J Heart Valve Dis 4 (1995), 160–165.
252. Ruiz, C.E., Jelnin, V., Kronzon, I., et al. Clinical outcomes in patients undergoing percutaneous closure of periprosthetic paravalvular leaks. J Am Coll Cardiol 58 (2011), 2210–2217.
253. Sorajja, P., Cabalka, A.K., Hagler, D.J., Rihal, C.S., Percutaneous repair of paravalvular prosthetic regurgitation: acute and 30-day outcomes in 115 patients. Circ Cardiovasc Interv 4 (2011), 314–321.
254. Sorajja, P., Cabalka, A.K., Hagler, D.J., Rihal, C.S., Long-term follow-up of percutaneous repair of paravalvular prosthetic regurgitation. J Am Coll Cardiol 58 (2011), 2218–2224.
255. Botelho-Nevers, E., Thuny, F., Casalta, J.P., et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med 169 (2009), 1290–1298.
256. Gordon, S.M., Serkey, J.M., Longworth, D.L., Lytle, B.W., Cosgrove, D.M. III, Early onset prosthetic valve endocarditis: the Cleveland Clinic experience 1992-1997. Ann Thorac Surg 69 (2000), 1388–1392.
257. Hasbun, R., Vikram, H.R., Barakat, L.A., Buenconsejo, J., Quagliarello, V.J., Complicated left-sided native valve endocarditis in adults: risk classification for mortality. JAMA 289 (2003), 1933–1940.
258. Jault, F., Gandjbakhch, I., Rama, A., et al. Active native valve endocarditis: determinants of operative death and late mortality. Ann Thorac Surg 63 (1997), 1737–1741.
259. Kiefer, T., Park, L., Tribouilloy, C., et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA 306 (2011), 2239–2247.
260. Tornos, P., Sanz, E., Permanyer-Miralda, G., Almirante, B., Planes, A.M., Soler-Soler, J., Late prosthetic valve endocarditis. Immediate and long-term prognosis. Chest 101 (1992), 37–41.
261. Wang, A., Athan, E., Pappas, P.A., et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 297 (2007), 1354–1361.
262. Aksoy, O., Sexton, D.J., Wang, A., et al. Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis 44 (2007), 364–372.
263. Chirouze, C., Cabell, C.H., Fowler, V.G. Jr., et al. Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration on Endocarditis merged database. Clin Infect Dis 38 (2004), 1323–1327.
264. Ellis, M.E., Al-Abdely, H., Sandridge, A., Greer, W., Ventura, W., Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 32 (2001), 50–62.
265. Hill, E.E., Herijgers, P., Claus, P., Vanderschueren, S., Herregods, M.C., Peetermans, W.E., Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J 28 (2007), 196–203.
266. Melgar, G.R., Nasser, R.M., Gordon, S.M., Lytle, B.W., Keys, T.F., Longworth, D.L., Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine (Baltimore) 76 (1997), 94–103.
267. Remadi, J.P., Habib, G., Nadji, G., et al. Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis. Ann Thorac Surg 83 (2007), 1295–1302.
268. Wolff, M., Witchitz, S., Chastang, C., Regnier, B., Vachon, F., Prosthetic valve endocarditis in the ICU. Prognostic factors of overall survival in a series of 122 cases and consequences for treatment decision. Chest 108 (1995), 688–694.
269. Anguera, I., Miro, J.M., Vilacosta, I., et al. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J 26 (2005), 288–297.
270. Chan, K.L., Early clinical course and long-term outcome of patients with infective endocarditis complicated by perivalvular abscess. CMAJ 167 (2002), 19–24.
271. Jault, F., Gandjbakhch, I., Chastre, J.C., et al. Prosthetic valve endocarditis with ring abscesses. Surgical management and long-term results. J Thorac Cardiovasc Surg 105 (1993), 1106–1113.
272. Middlemost, S., Wisenbaugh, T., Meyerowitz, C., et al. A case for early surgery in native left-sided endocarditis complicated by heart failure: results in 203 patients. J Am Coll Cardiol 18 (1991), 663–667.
273. Wang, K., Gobel, F., Gleason, D.F., Edwards, J.E., Complete heart block complicating bacterial endocarditis. Circulation 46 (1972), 939–947.
274. Hill, E.E., Herijgers, P., Claus, P., Vanderschueren, S., Peetermans, W.E., Herregods, M.C., Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome: a 5-year study. Am Heart J 154 (2007), 923–928.
275. Klieverik, L.M.A., Yacoub, M.H., Edwards, S., et al. Surgical treatment of active native aortic valve endocarditis with allografts and mechanical prostheses. Ann Thorac Surg 88 (2009), 1814–1821.
276. Manne, M.B., Shrestha, N.K., Lytle, B.W., et al. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg 93 (2012), 489–493.
277. Athan, E., Chu, V.H., Tattevin, P., et al. Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA 307 (2012), 1727–1735.
278. Ho, H.H., Siu, C.W., Yiu, K.H., Tse, H.F., Chui, W.H., Chow, W.H., Prosthetic valve endocarditis in a multicenter registry of Chinese patients. Asian Cardiovasc Thorac Ann 18 (2010), 430–434.
279. Rundström, H., Kennergren, C., Andersson, R., Alestig, K., Hogevik, H., Pacemaker endocarditis during 18 years in Göteborg. Scand J Infect Dis 36 (2004), 674–679.
280. Sohail, M.R., Uslan, D.Z., Khan, A.H., et al. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin Proc 83 (2008), 46–53.
281. Kang, D.H., Kim, Y.J., Kim, S.H., et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med 366 (2012), 2466–2473.
282. Mügge, A., Daniel, W.G., Frank, G., Lichtlen, P.R., Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol 14 (1989), 631–638.
283. Thuny, F., Di Salvo, G., Belliard, O., et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation 112 (2005), 69–75.
284. Eishi, K., Kawazoe, K., Kuriyama, Y., Kitoh, Y., Kawashima, Y., Omae, T., Surgical management of infective endocarditis associated with cerebral complications. Multi-center retrospective study in Japan. J Thorac Cardiovasc Surg 110 (1995), 1745–1755.
285. Barsic, B., Dickerman, S., Krajinovic, V., et al. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis 56 (2013), 209–217.
286. García-Cabrera, E., Fernández-Hidalgo, N., Almirante, B., et al. Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation 127 (2013), 2272–2284.